Collectively, these studies pinpointed that CD38 is crucial for in vivo Treg modulatory functions and generation, and confirmed CD38 targeting approach by mAbs as efficient treatment to deplete CD38hi Tregs and revert tumor-induced immune-modulation. This evidence concerns the gene CD38 and neoplasm.